News
Another AIM defection as BiVictriX plans to delist
The list of UK biotechs deciding to abandon listings on the AIM …
19698 items found
News
FDA clears first anaphylaxis nasal spray at second attempt
ARS Pharma has claimed FDA approval for its epinephrine nasal spray …
News
MSD adds bispecific cancer antibody via $1.3bn Curon deal
MSD has an extensive pipeline in oncology but hasn't been a player in …
News
FDA shoots down Lykos' MDMA therapy for PTSD
The FDA has denied Lykos Therapeutics' marketing application for its …
News
Lilly's tau drug for Alzheimer's flunks phase 2 test
Eli Lilly is still celebrating the FDA approval of its …
R&D
Partner Content
R&D
Partner Content
The 5th Commercializing Flow Chemistry Summit
The 5th Commercializing Flow Chemistry Summit marks a pivotal year, …
News
Second time lucky at FDA for Citius' lymphoma drug
At the second attempt, the FDA has approved Citius Pharmaceuticals' …
Oncology
Partner Content
Personalized Cancer Vaccine Summit
The Personalized Cancer Vaccine Summit, formerly known as mRNA Cancer …
News
More bad news for TIGIT as MSD stops another trial
Another TIGIT trial failure has been abandoned, casting a shadow once …
Sales & Marketing
Minutes to answers: Compliant chat builds more meaningful HCP relationships
As therapies become more complex, field reps and doctors are finding …
News
Lilly says tirzepatide supply issues are resolving
Eli Lilly has raised its revenue guidance for 2024 by $3 billion, …
News
Roche trial confirms Vabysmo efficacy in minorities
A study has shown that Roche's diabetic macular oedema (DME) therapy Vabysmo is effective in patients who identify as African American, Black, Hispanic and Latino, plugging a gap in the dat
Digital
Sponsored
Decoding physician prescribing behaviour: A data-driven jour...
Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge.
Sales & Marketing
Deep Dive: Commercialisation 2024
In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
Digital
Access to genomic surveillance: Open science and public heal...
The pandemic served as a catalyst for a revolution in genomic surveillance for tracking pathogens.
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
BIO-Europe's 30th Anniversary Landmark Event in Stockholm
BIO-Europe™ celebrates 30 years of facilitating partnerships this Fall. In 1994, BIO-Europe launched with the mission to drive biotech innovation and
R&D
Partner Content
8th Dermatology Drug Development Summit
Industry’s Destination to Discover & Develop Best-In-Class Drugs for Immuno-Inflammatory Skin Disease
